

ENZYMATIC THERADY

What **Better** feels like~

INTEGRATIVE THERAPEUTICS INC." NF Formulas PhytoPharmica

Tyler Encapsulations Vitaline Formulas

9755 SW Commerce Circle, Suite B2 Wilsonville, OR 97070 P: 503.582.8386 F: 503.582.0467 ENZYMATIC THERAPY' PHYTOPHARMICA'

825 Challenger Drive, Green Bay, WI 54311-8328 P: 920,469 1313 F: 888,570.6460 (Enzymatic) F: 503.582.0467 P. 920.469.9099 F: 920.469.4418 (Phyto)

APR 2 0 2004

April 13, 2004

Office of Nutritional Products, Labeling & Dietary Supplements, HFS 810 Center for Food Safety and Applied Nutrition Food and Drug Administration 5100 Paint Branch Parkway College Park, MD 20740

RE:

Label Claims/Disclaimers

Dear Sir or Madam:

This letter is to notify you that the following product is Manufactured, Packed, and/or Distributed by Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 has a label that contains a statement provided by section 403(r)(6) of the Federal Food, Drug and Cosmetic Act. Enzymatic Therapy, Inc. wishes to take advantage of the exemption to section 201(g)(1)(C) of the act and comply with section 403(r)(6) of the act. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

| PRODUCT NAME | STATEMENTS | INGREDIENT(S) TO WHICH THE CLAIM REFERS |
|-----------------|--|---|
| Adren-Comp™* | This formula also includes extracts of bupleurum chinense root. Its active components are known as saikosaponins, which apparently support the healthy release of cortisone and other hormones by the adrenal gland, making them more potent.* | Bupleurum Chinense Root |

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

| | KLICILA |
|-----|---------|
| By: | 1 |

Robert C. Doster

Title: Senior Vice President of Scientific Affairs

Date: $\frac{4}{13}/64$

LET 13899

The second section of the second section is a second section of the second section of the second section is a second section of the section of

975 0162

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs at (920) 469-3608.

Sincerely.

Michael P. Devereux Chief Financial Officer